Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SSY GroupHKSE:02005 -0.42%86 Market Cap is HK$6,911 Mil as of Jul. 27, 2026. GuruFocus rates HKSE:02005 with a GF Score™ of 86/100 and a GF Value™ of HK$3.04 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 1,024 Drug Manufacturers companies, SSY Group ranks better than 71.97% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). SSY Group's share price for the quarter that ended in Dec. 2025 was HK$2.83. SSY Group's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 2,905 Mil. Therefore, SSY Group's market cap for the quarter that ended in Dec. 2025 was HK$8,221 Mil.
SSY Group's quarterly market cap
declined
from Dec. 2024 (HK$10,616 Mil) to Jun. 2025 (HK$8,158 Mil) but then
increased
from Jun. 2025 (HK$8,158 Mil) to Dec. 2025 (HK$8,221 Mil).
SSY Group's annual market cap
declined
from Dec. 2023 (HK$14,651 Mil) to Dec. 2024 (HK$10,616 Mil) and
declined
from Dec. 2024 (HK$10,616 Mil) to Dec. 2025 (HK$8,221 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. SSY Group's Enterprise Value for Today is HK$9,537 Mil.
SSY Group (HKSE:02005) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
SSY Group Market Cap Related Terms
SSY Group Market Cap Historical Data
* Premium members only.
The historical data trend for SSY Group's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, SSY Group's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SSY Group Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SSY Group's Market Cap distribution charts can be found below:
* The bar in red indicates where SSY Group's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
SSY Group's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SSY Group (HKSE:02005) has a Market Cap of HK$6,911 Mil as of Jul. 27, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on SSY Group and its competitors. According to the industry distribution chart, SSY Group ranks #287 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 28%.
Is SSY Group's Market Cap too high?
SSY Group's current Market Cap is HK$6,911 Mil. Based on the distribution chart, SSY Group ranks #287 out of 1024 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, SSY Group has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does SSY Group's Market Cap compare to ZTS?
According to the Drug Manufacturers industry distribution chart, SSY Group ranks #287 out of 1024 companies for Market Cap. This puts SSY Group in the upper half of its industry. The industry median Market Cap is 208.62. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 208.62, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on SSY Group and its competitors. For the Drug Manufacturers industry, the median Market Cap is 208.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SSY Group's current Market Cap is HK$6,911 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SSY Group stock overvalued right now?
Based on GuruFocus' analysis, SSY Group (HKSE:02005) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$3.04, compared to a current price of HK$2.39 — trading 21.4% below its estimated fair value. The current Market Cap is HK$6,911 Mil. SSY Group's overall GF Score™ is 86/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For SSY Group (HKSE:02005), the current Market Cap is HK$6,911 Mil as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SSY Group (HKSE:02005) Overvalued in 2026?
Based on GuruFocus' analysis, SSY Group stock appears to be undervalued.
The current stock price of HK$2.39 is trading 21.4% below its estimated GF Value™ of HK$3.04.
GuruFocus considers SSY Group to be Modestly Undervalued.
Key valuation signals for HKSE:02005:
Market Cap: HK$6,911 Mil
GF Value™: HK$3.04 vs. price of HK$2.39 (21.4% below fair value)
No single metric tells the full story. See the HKSE:02005 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SSY Group Ltd is engaged in the research, development, manufacturing, and selling of a wide range of pharmaceutical products, which include finished medicines of mainly intravenous infusion solutions and ampoule injections to hospitals and distributors, bulk pharmaceuticals, and medical materials. The company has two reportable segments, including intravenous infusion solutions and other medical materials. The company derives a vast majority of its revenue principally from the Intravenous infusion solution and others. Revenue generation is driven mostly by its sales of pharmaceutical products. The company derives maximum revenue from PRC.
86GF Score
Get the complete analysis for HKSE:02005
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02005 has been successfully added to your 
